Cancer is not a single disease caused by a single genetic mistake. It is an evolving population of cells.
A tumor begins when cells acquire changes that allow them to grow, divide, or survive when they normally would not. As those cells multiply, additional changes arise. Some give individual cancer cells an advantage over their neighbors: faster growth, resistance to cell death, better access to nutrients, or the ability to withstand treatment. Cells with useful advantages can become more abundant, while less competitive cells may disappear.
This process is called cancer evolution. It helps explain why tumors can become more aggressive, why cancers within the same tumor can be genetically different from one another, and why a treatment that initially works can sometimes stop working.
Understanding cancer evolution also changes how we think about cancer treatment. The problem is not simply to destroy abnormal cells. It is to understand a moving target whose characteristics can change as the disease develops and as its environment changes.
What cancer evolution means
Cancer evolution is the process by which cancer-cell populations change over time through the combined effects of genetic alterations, cell reproduction, selection, and the tumor’s environment.
The underlying principle is similar to evolution elsewhere in biology: populations contain variation, and conditions favor some variants over others. But cancer evolution happens within an individual and over a much shorter timescale than the evolution of species.
Cancer cells acquire changes in their DNA and in the way their genes are regulated. Many of these changes have little or no immediate benefit. Others can alter important behaviors such as cell division, DNA repair, metabolism, movement, or sensitivity to signals from surrounding cells.
When a change gives a cell a reproductive or survival advantage, that cell can produce more descendants. Over time, its descendants may make up a larger fraction of the tumor.
The result is a tumor that is often heterogeneous, meaning that it contains multiple populations of cancer cells with different molecular characteristics.
How a tumor acquires variation
Cancer evolution depends on variation. One important source is mutation: a change in the DNA sequence.
Mutations can arise from mistakes during DNA replication, damage to DNA, or failures in the mechanisms that normally repair DNA. Some cancers also develop extensive genomic instability, in which chromosomes or larger portions of the genome are repeatedly gained, lost, rearranged, or otherwise altered.
Not every genetic alteration matters equally. A useful distinction is between driver alterations and passenger alterations.
A driver alteration contributes to cancer development or gives a cancer cell an advantage under particular conditions. A passenger alteration is carried along because it occurred in a cell that happened to expand, without itself providing a meaningful advantage.
Drivers can affect several major cellular systems. They may activate growth-promoting pathways, disable mechanisms that restrain cell division, interfere with programmed cell death, or impair DNA-damage responses.
Cancer cells can also change without altering the DNA sequence itself. Epigenetic changes affect which genes are active or inactive and can sometimes be reversible. These changes provide another layer of variation on which selection can act.
Importantly, cancer evolution does not require every cancer cell to acquire changes at the same rate or in the same way. Different branches of a tumor’s cell population can accumulate different alterations.
A tumor is more like a branching population than a uniform mass
Early in tumor development, a cell with a cancer-promoting alteration can give rise to a growing population of related cells. As that population expands, some descendants acquire additional changes.
This can produce a branching pattern:
- One population may retain an alteration shared by much of the tumor.
- A later alteration may occur in only one branch.
- That branch may expand and become a substantial part of the tumor.
- Other branches may persist at low levels or disappear.
This is one reason why two samples taken from different parts of the same tumor can sometimes show different molecular features.
The distinction between clonal and subclonal alterations is useful here. A clonal alteration is present in a large common population of tumor cells, whereas a subclonal alteration occurs in only a subset.
Tumor evolution can therefore produce a mixture of related but genetically distinct cell populations. The composition of that mixture can change over time.
Natural selection shapes which cancer cells survive
Genetic variation alone does not explain tumor progression. The environment determines which characteristics are advantageous.
A cell that grows rapidly may have an advantage when resources are plentiful. But rapid growth may also increase its dependence on particular nutrients or signaling pathways. Under different conditions, another population may be better suited to survive.
The tumor microenvironment—the normal and abnormal cells, molecules, blood vessels, and physical conditions surrounding cancer cells—can exert strong selective pressure.
For example, regions of a tumor may have limited oxygen because blood vessels cannot adequately supply all of the growing tissue. Hypoxia, or low oxygen availability, can favor cells capable of adapting to those conditions.
Tumors also interact with immune cells. The immune system can recognize and eliminate some abnormal cells, creating pressure that favors cancer cells better able to avoid immune detection or resist immune attack.
Other pressures include competition for nutrients, physical constraints, signals from nearby normal cells, and changes caused by previous treatments.
The important point is that an advantageous trait is not inherently advantageous in every setting. Its value depends on the conditions surrounding the cancer cells.
Why cancer treatment can drive evolution
Treatment is one of the strongest selective pressures a tumor can experience.
Suppose a tumor contains millions of cells and most are sensitive to a particular drug, while a small population has a characteristic that allows it to survive exposure. Treatment can eliminate the sensitive cells while leaving the resistant population behind. With less competition, those surviving cells may expand.
This is often described as selection for resistance.
Resistance can arise through several mechanisms. A cancer cell may acquire or already possess an alteration that changes the drug’s target. It may reduce the amount of drug that reaches the relevant part of the cell, alter how the drug is processed, or activate an alternative pathway that allows growth to continue.
Some resistant states involve changes in cell behavior rather than a permanent DNA mutation. Cancer cells can sometimes enter cellular states that make them less vulnerable to treatment and may later change again.
Treatment resistance therefore does not necessarily mean that a drug somehow “teaches” every cancer cell how to resist it. More often, treatment changes the population by removing cells that are vulnerable and leaving cells with pre-existing or subsequently acquired survival advantages.
Drug resistance is an evolutionary problem
The evolution of resistance is one of the clearest clinical consequences of tumor evolution.
A treatment may initially shrink a tumor because it eliminates a large fraction of cancer cells. Yet a small surviving population can remain. If those cells can reproduce under continued treatment, the cancer may eventually progress.
Resistance can also arise through more than one route at the same time. Different groups of cells within the same tumor may use different mechanisms to survive the same therapy.
This creates an important challenge: a treatment that targets one dominant population may leave other populations largely unaffected.
The evolutionary history of a cancer also matters. Previous treatments can change which populations remain, meaning that the tumor encountered later in the disease may be biologically different from the tumor that existed before treatment.
Metastasis involves another round of selection
Cancer evolution is also central to metastasis, the spread of cancer cells from their original site to distant parts of the body.
To form a metastasis, a cancer cell generally must accomplish a series of difficult tasks. It must leave the primary tumor, survive movement through the body, enter a distant tissue, adapt to a new environment, and establish a population there.
Most cancer cells may not be capable of completing this sequence successfully. Cells that can do so may possess particular combinations of genetic and cellular characteristics.
The resulting metastases can therefore differ from the original tumor. They may also differ from one another because each metastatic site presents a distinct environment and may be founded by different cancer-cell populations.
This helps explain why cancer is often best understood as a collection of evolving populations distributed across different locations in the body rather than as one genetically uniform disease.
The tumor microenvironment is part of the evolutionary process
Cancer cells do not evolve in isolation.
Tumors contain many noncancerous cells, including immune cells, fibroblasts, endothelial cells that form blood vessels, and other supporting cell types. They also contain extracellular material and signaling molecules that influence how cells behave.
These surroundings can provide growth signals, alter metabolism, affect immune responses, and influence how cancer cells respond to treatment.
The relationship can work in both directions. Cancer cells can alter their surroundings, while the altered environment can in turn favor particular cancer-cell populations.
This means that the evolution of a tumor is partly an interaction between the cancer cells and the ecosystem in which they live.
Why the same cancer can behave differently in different people
Cancer evolution helps explain why cancers with the same broad diagnosis can behave differently.
Two tumors classified as the same cancer type may have different genetic alterations, different mixtures of subclones, and different microenvironments. Even when two tumors share an important driver alteration, additional changes can influence how they grow and respond to treatment.
The evolutionary history of each tumor is shaped by chance events as well as selection. A mutation that happens early can be inherited by many later cancer cells; the same mutation occurring much later may remain confined to a small subpopulation.
As a result, the label used to diagnose a cancer captures only part of its biology.
What this means for cancer treatment
Modern oncology increasingly accounts for the molecular characteristics of tumors. Targeted therapies, immunotherapies, hormone therapies, chemotherapy, radiation, and other treatments impose different kinds of pressure on cancer-cell populations.
Molecular testing can identify alterations that may be relevant to treatment. But a single biopsy provides a snapshot. Because tumors can contain multiple populations, the sampled tissue may not represent every important subclone.
This does not make tumor testing unhelpful. It highlights why treatment decisions sometimes require information from more than one source and why disease can change after treatment.
Researchers are also investigating ways to use evolutionary principles directly in treatment. One approach is to consider not only which cancer cells are most sensitive to a drug, but also how treatment changes competition among different populations. In some circumstances, maintaining a population of treatment-sensitive cells could theoretically limit the expansion of resistant cells. This idea, known as adaptive therapy, remains an area of research and is not appropriate for every cancer or patient.
Another strategy is combination treatment: attacking different vulnerabilities simultaneously can make it harder for a single cancer-cell population to survive. The success of such approaches depends on the particular cancer, the targets involved, toxicity, and how the tumor evolves.
Cancer evolution is not the same as purposeful adaptation
It is tempting to describe a tumor as if it were consciously responding to treatment or deliberately finding ways to survive. That framing is misleading.
Cancer cells do not anticipate future conditions. Evolution works through variation and selection.
Changes arise through biological processes, including mutation and changes in gene regulation. The surrounding conditions then influence which cells survive and reproduce. A population may therefore become better suited to a new environment without any individual cell having a goal or plan.
The distinction matters because it explains both the power and the limits of cancer evolution. Tumors can evolve remarkable resistance and flexibility, but their behavior is constrained by the biological changes available to them and by the environments in which they must survive.
The central idea: cancer is a moving population
Cancer evolution provides a framework for connecting many otherwise puzzling features of cancer: genetic heterogeneity, tumor progression, treatment resistance, recurrence, and metastasis.
A tumor changes because its cells are not identical and because their environment continually changes the advantages and disadvantages of different traits. Treatment can remove vulnerable populations and favor resistant ones. A growing tumor can create oxygen and nutrient shortages that favor other adaptations. Spread to a new organ introduces yet another environment and another evolutionary challenge.
For patients and clinicians, this means that cancer is not always a fixed molecular target. It is a dynamic population whose composition can change throughout the course of disease.
That is why understanding a cancer’s evolutionary history—and anticipating how treatment may reshape its remaining populations—is an important part of modern cancer research.
